Endocrinology and hormone therapy in breast cancer: New insight into estrogen receptor-α function and its implication for endocrine therapy resistance in breast cancer

by Schiff, Rachel, Osborne, C Kent
Published 2005

MECHANISMS OF ENDOCRINE RESISTANCE IN BREAST CANCER

by Osborne, C Kent, Schiff, Rachel
Published 2011

Therapy for Cancer of the Breast: Current Status of Steroid Hormone Receptors

by Osborne, C. Kent, McGuire, William L.
Published 1979

Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer

by Fu, Xiaoyong, Osborne, C. Kent, Schiff, Rachel
Published 2013

DE-ESCALATING TREATMENT FOR HER2-POSITIVE EARLY BREAST CANCER

by OSBORNE, C. KENT, SCHIFF, RACHEL, RIMAWI, MOTHAMAR
Published in Trans Am Clin Climatol Assoc (2020)

Antagonism between Epidermal Growth Factor and Phorbol Ester Tumor Promoters in Human Breast Cancer Cells

by Osborne, C. Kent, Hamilton, Barbara, Nover, Marianne, Ziegler, Jeanette
Published 1981

Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance

by Arpino, Grazia, Wiechmann, Lisa, Osborne, C. Kent, Schiff, Rachel
Published 2008

The Changing Role of ER in Endocrine Resistance

by Nardone, Agostina, De Angelis, Carmine, Trivedi, Meghana V., Osborne, C. Kent, Schiff, Rachel
Published in Breast (2015)

Towards personalized treatment for early stage HER2-positive breast cancer

by Goutsouliak, Kristina, Veeraraghavan, Jamunarani, Sethunath, Vidyalakshmi, De Angelis, Carmine, Osborne, C. Kent, Rimawi, Mothaffar F., Schiff, Rachel
Published in Nat Rev Clin Oncol (2019)

EGFR Expression in Breast Cancer Association with biologic phenotype and clinical outcomes

by Rimawi, Mothaffar F., Shetty, Priya B., Weiss, Heidi L., Schiff, Rachel, Osborne, C. Kent, Chamness, Gary C., Elledge, Richard M.
Published 2010

De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance

by Veeraraghavan, Jamunarani, De Angelis, Carmine, Reis-Filho, Jorge S., Prat, Aleix, Rimawi, Mothaffar F., Pascual, Tomás, Osborne, C. Kent, Schiff, Rachel
Published in Breast (2017)

Development of resistance to targeted therapies transforms the clinically-associated molecular profile subtype of breast tumor xenografts

by Creighton, Chad J., Massarweh, Suleiman, Huang, Shixia, Tsimelzon, Anna, Shou, Jiang, Malorni, Luca, Hilsenbeck, Susan G., Osborne, C. Kent, Schiff, Rachel
Published 2008

Treatment Quality and Outcomes of African American Versus White Breast Cancer Patients: Retrospective Analysis of Southwest Oncology Studies S8814/S8897

by Hershman, Dawn L., Unger, Joseph M., Barlow, William E., Hutchins, Laura F., Martino, Silvana, Osborne, C. Kent, Livingston, Robert B., Albain, Kathy S.
Published 2009

THERAPEUTIC POTENTIAL OF THE DUAL EGFR/HER2 INHIBITOR AZD8931 IN CIRCUMVENTING ENDOCRINE RESISTANCE

by Morrison, Gladys, Fu, Xiaoyong, Shea, Marty, Nanda, Sarmistha, Giuliano, Mario, Wang, Tao, Klinowska, Teresa, Osborne, C. Kent, Rimawi, Mothaffar F., Schiff, Rachel
Published 2014

Estrogen Receptor β Protein in Human Breast Cancer: Correlation with Clinical Tumor Parameters

by Fuqua, Suzanne A.W., Schiff, Rachel, Parra, Irma, Moore, John T., Mohsin, Syed K., Osborne, C. Kent, Clark, Gary M., Allred, D. Craig
Published in Cancer Res (2003)

Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer

by Migliaccio, Ilenia, Wu, Meng-Fen, Gutierrez, Carolina, Malorni, Luca, Mohsin, Syed K., Allred, D. Craig, Hilsenbeck, Susan G., Osborne, C. Kent, Weiss, Heidi, Lee, Adrian V.
Published 2009

β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib

by Huang, Catherine, Park, Catherine C, Hilsenbeck, Susan G, Ward, Robin, Rimawi, Mothaffar F, Wang, Yen-chao, Shou, Jiang, Bissell, Mina J, Osborne, C Kent, Schiff, Rachel
Published 2011

Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer

by Guarducci, Cristina, Bonechi, Martina, Benelli, Matteo, Biagioni, Chiara, Boccalini, Giulia, Romagnoli, Dario, Verardo, Roberto, Schiff, Rachel, Osborne, C. Kent, De Angelis, Carmine, Di Leo, Angelo, Malorni, Luca, Migliaccio, Ilenia
Published in NPJ Breast Cancer (2018)

Trastuzumab resistant HER2+ breast cancer cells retain sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition

by Wielgos, Monica E., Zhang, Zhuo, Rajbhandari, Rajani, Cooper, Tiffiny S., Zeng, Ling, Forero, Andres, Esteva, Francisco J., Osborne, C. Kent, Schiff, Rachel, LoBuglio, Albert F., Nozell, Susan E., Yang, Eddy S.
Published in Mol Cancer Ther (2018)

Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: a Randomized Phase II Study

by Osborne, C. Kent, Neven, Patrick, Dirix, Luc Y., Mackey, John R., Robert, Jean, Underhill, Craig, Schiff, Rachel, Gutierrez, Carolina, Migliaccio, Ilenia, Anagnostou, Valsamo K., Rimm, David L., Magill, Patrick, Sellers, Mark
Published 2011